Tyrosine kinase inhibitors (TKIs) are medications used to treat chronic myeloid leukemia. These drugs work by blocking specific proteins (tyrosine kinases) that are responsible for the growth of cancer cells. TKIs help control the disease by preventing the abnormal white blood cells from multiplying. This study looks at how these medications can be reduced in dosage while maintaining their effectiveness in treating leukemia.

Note: Since the source data doesn’t specify which particular TKIs are being used in this trial, I can only provide a general description of this class of medications. Common TKIs used in chronic myeloid leukemia treatment include imatinib, nilotinib, and dasatinib, but the specific ones used in this trial are not mentioned in the provided data.

Chronic Myeloid Leukemia – A blood and bone marrow cancer that develops when the bone marrow makes too many white blood cells. The condition begins in a blood-forming cell of the bone marrow that produces too many abnormal white blood cells called granulocytes. These abnormal cells grow slowly but eventually crowd out healthy blood cells in the bone marrow. The disease typically progresses through three phases: chronic phase, accelerated phase, and blast phase. During the chronic phase, which can last several years, patients may have few or no symptoms as the disease develops gradually. The condition is characterized by the presence of an abnormal chromosome called the Philadelphia chromosome.